Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Kymab Group Ltd.
DescriptionAnti-LIGHT mAb
Molecular Target Tumor necrosis factor (TNF) ligand superfamily member 14 (TNFSF14) (LIGHT) (CD258)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today